Abbott “Knolls” When To Quit: Large-Scale Mergers Not On Agenda, CEO Says

Abbott's acquisition of Knoll has given the company enough "critical mass" to meet its pharmaceutical growth goals, Abbott CEO Miles White indicated during an investor call Jan. 16